To many biopharmaceutial executives and investors, the start of 2026 felt like a new dawn. A lengthy pullback finally abated towards the end of 2025, as a wave of dealmaking, financings and positive clinical trial readouts lifted drug companies and revitalized broader investor interest. Stock prices climbed as several advancing companies weren’t only seen as acquisition targets, but potentially secure long-term investments that could become profitable in the future. The Trump administration’s drug pricing and tariff threats have appeared manageable, too. Yet that newfound optimism is also mixed with an underlying tension.
Read the full article: The Biopharma Industry Outlook on 2026: Optimism and Tension //
Source: https://www.biopharmadive.com/news/biotech-pharma-trends-outlook-2026/810833/